BPI-23314: A novel orally bioavailable small molecular BET inhibitor with target protein degradation activity

被引：0
|
作者：
Guo, Jing [1 ]
Xu, Yan [1 ]
Yan, Dan [1 ]
Yu, Bo [1 ]
Yu, Weiwei [1 ]
Chen, Haibo [1 ]
Xu, Xiaofeng [1 ]
Liu, Xiangyong [1 ]
Lan, Hong [1 ]
Ding, Lieming [1 ]
Wang, Jiabing [1 ]
机构：
[1] Betta Pharmaceut Co LTD, Hangzhou, Peoples R China
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-1751
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1751
引用
收藏
页数：2
相关论文
共 50 条
  • [21] CB-708, an orally bioavailable small molecule inhibitor of CD73 with immunostimulatory and anti-tumor activity
    Lee, Clarissa
    Bhupathi, Deepthi
    Billedeau, Roland
    Chen, Jason
    Chen, Lijing
    Dang, Rosalyn
    Gross, Matthew
    Huang, Tony
    Li, Weiqun
    Ma, Yong
    MacKinnon, Andrew
    Marguier, Gisele
    Neou, Silinda
    Parlati, Francesco
    Sotirovska, Natalija
    Spurlock, Sandra
    Stanton, Timothy
    Steggerda, Susanne
    Zhang, Jing
    Zhang, Winter
    Li, Jim
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [22] Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
    McMillin, Douglas W.
    Ooi, Melissa
    Delmore, Jake
    Negri, Joseph
    Hayden, Patrick
    Mitsiades, Nicolas
    Jakubikova, Jana
    Maira, Sauveur-Michel
    Garcia-Echeverria, Carlos
    Schlossman, Robert
    Munshi, Nikhil C.
    Richardson, Paul G.
    Anderson, Kenneth C.
    Mitsiades, Constantine S.
    CANCER RESEARCH, 2009, 69 (14) : 5835 - 5842
  • [23] A PHASE 1 STUDY OF MP470, A NOVEL ORALLY BIOAVAILABLE SMALL MOLECULE WITH RAD 51 SUPPRESSION ACTIVITY
    Tibes, R.
    Berk, G.
    Fine, G. D.
    Choy, G. S.
    Tolcher, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 160 - 160
  • [24] A novel orally-bioavailable small-molecule inhibitor of Stat3 regresses human breast and lung cancer xenografts
    Yue, Peibin
    Zhang, Xiaolei
    Page, Brent D. G.
    Zhao, Wei
    Paladino, David
    Gunning, Patrick T.
    Turkson, James
    CANCER RESEARCH, 2012, 72
  • [25] Commentary on "Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa": Small molecule factor XIa inhibitor asundexian allows for safer anticoagulation COMMENT
    Mailer, Reiner K.
    Renne, Thomas
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2022, 20 (06) : 1309 - 1311
  • [26] Novel orally bioavailable macrocycles that target cyclin A and B elicit antitumor activity in breast cancer patient-derived xenograft models
    Dias, Mariana Paes
    Liu, Li-Fen
    Levin, Bernard
    Molina, Cristina
    Guzman, Marla
    Rodriguez, Olga
    Wang, Evelyn W.
    Serra, Violeta
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [27] In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells
    Chauhan, Dharminder
    Tian, Ze
    Zhou, Bin
    Kuhn, Deborah
    Orlowski, Robert
    Raje, Noopur
    Richardson, Paul
    Anderson, Kenneth C.
    CLINICAL CANCER RESEARCH, 2011, 17 (16) : 5311 - 5321
  • [28] Preclinical Activity of the Novel Orally Bioavailable HSP90 Inhibitor NVP-HSP990 against Multiple Myeloma Cells
    Stuehmer, Thorsten
    Iskandarov, Kamol
    Gao, Zhenhai
    Bumm, Thomas
    Grella, Evelyn
    Jensen, Michael R.
    Einsele, Hermann
    Chatterjee, Manik
    Bargou, Ralf C.
    ANTICANCER RESEARCH, 2012, 32 (02) : 453 - 462
  • [29] AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
    Chresta, Christine M.
    Davies, Barry R.
    Hickson, Ian
    Harding, Tom
    Cosulich, Sabina
    Critchlow, Susan E.
    Vincent, John P.
    Ellston, Rebecca
    Jones, Darren
    Sini, Patrizia
    James, Dominic
    Howard, Zoe
    Dudley, Phillippa
    Hughes, Gareth
    Smith, Lisa
    Maguire, Sharon
    Hummersone, Marc
    Malagu, Karine
    Menear, Keith
    Jenkins, Richard
    Jacobsen, Matt
    Smith, Graeme C. M.
    Guichard, Sylvie
    Pass, Martin
    CANCER RESEARCH, 2010, 70 (01) : 288 - 298
  • [30] Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B
    Andersen, HS
    Olsen, OH
    Iversen, LF
    Sorensen, ALP
    Mortensen, SB
    Christensen, MS
    Branner, S
    Hansen, TK
    Lau, JF
    Jeppesen, L
    Moran, EJ
    Su, J
    Bakir, F
    Judge, L
    Shahbaz, M
    Collins, T
    Vo, T
    Newman, MJ
    Ripka, WC
    Moller, NPH
    JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (20) : 4443 - 4459
12345